Pregabalin open-label, multicenter add-on trial following a 4-day double-blind transition period to determine long-term safety and efficacy in patients with partial seizures
Latest Information Update: 01 Oct 2006
At a glance
- Drugs Pregabalin (Primary)
- Indications Partial epilepsies
- Focus Therapeutic Use
- Sponsors Pfizer
- 01 Oct 2006 New trial record.